Meeting
2023 ASCO Genitourinary Cancers Symposium
Cardiovascular and thromboembolic events associated with intense neoadjuvant androgen deprivation therapy followed by prostatectomy in patients with localized prostate cancer: A meta-analysis of clinical trials.
Authors
Eduardo Felicio Campos
Instituto de Ensino e Pesquisa - IEP, São Paulo, SC, Brazil
Eduardo Felicio Campos , Camila Bragança Xavier , Marcello Moro Queiroz , Nildevande Firmino Lima Jr., Denis L. Jardim , Diogo Assed Bastos , Eder Nisi Ilario , Rafael Ferreira Coelho , William Carlos Nahas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 341)
DOI
10.1200/JCO.2023.41.6_suppl.341
Abstract #
341
Poster Bd #
L19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Planned interim analysis of perioperative safety of fluzoparib combined with abiraterone in the neoadjuvant treatment of locoregional high-risk prostate cancer: Results from multicenter, phase 2 FAST-PC trial.
First Author: Yao Zhu
Poster
2018 Genitourinary Cancers Symposium
Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).
First Author: Rana R. McKay
Poster
2024 ASCO Genitourinary Cancers Symposium
Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial.
First Author: Rana R. McKay
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang